Program: RRPV

Solicitation Number: RFI Oral Formulation Vaccines

Customer: BARDA

Release Date: 03/04/2024

Submission Deadline: 04/19/2024

Description: information to better refine the requirements for oral vaccine formulations under Project NextGen using BARDA’s Rapid Response Partnership Vehicle (RRPV). The challenges associated with oral vaccine manufacturing include maintaining antigen stability, navigating the gastrointestinal environment, and achieving scalable and cost-effective manufacturing processes. To address these limitations, BARDA wishes to identify and advance innovative approaches for oral formulation of vaccines. BARDA envisions that advancing oral formulation could improve vaccine’s efficacy, uptake, compliance, and accessibility. The information requested from this RFI will serve as continued market research in support of a potential program under BARDA’s RRPV, wherein BARDA would partner with organizations to work towards fulfilling the goals of the Project NextGen Enablers Program.


solicitation_program: RRPV

solicitation_number: RFI Oral Formulation Vaccines

solicitation_customer: BARDA

solicitation_release_date: 03/04/2024

solicitation_submission_deadline: 04/19/2024

solicitation_description: Requesting project proposals from product developers for the advanced clinical development and assessment of Next-Generation Therapeutics for COVID-19. BARDA has previously identified a capability gap for therapeutics that provide protection through pre-exposure prophylaxis (PrEP) and treatment against new SARS-CoV-2 variants. The purpose of this project is to partner with developers and other organizations to advance the clinical development of Next-Generation Therapeutics for COVID-19, specifically treatment.


Our Collaborations